This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by la Porte, C. J. L.
Right arrow Articles by Cameron, D. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by la Porte, C. J. L.
Right arrow Articles by Cameron, D. W.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, January 2009, p. 162-173, Vol. 53, No. 1
0066-4804/09/$08.00+0     doi:10.1128/AAC.00534-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.

Interaction Studies of Tipranavir-Ritonavir with Clarithromycin, Fluconazole, and Rifabutin in Healthy Volunteers{triangledown}

Charles J. L. la Porte,1* John P. Sabo,2 Mabrouk Elgadi,3 and D. William Cameron1

University of Ottawa, The Ottawa Hospital and Ottawa Health Research Institute, Ottawa, Canada,1 Boehringer Ingelheim Pharmaceuticals, Ridgefield, Connecticut,2 Boehringer Ingelheim Canada Ltd., Burlington, Ontario, Canada3

Received 24 April 2008/ Returned for modification 23 June 2008/ Accepted 4 November 2008

Three separate controlled, two-period studies with healthy volunteers assessed the pharmacokinetic interactions between tipranavir-ritonavir (TPV/r) in a 500/200-mg dose and 500 mg of clarithromycin (CLR), 100 mg of fluconazole (FCZ), or 150 mg of rifabutin (RFB). The CLR study was conducted with 24 subjects. The geometric mean ratios (GMR) and 90% confidence intervals (90% CI; given in parentheses) of the areas under the concentration-time curve (AUC), the maximum concentrations of the drugs in serum (Cmax), and the concentrations in serum at 12 h postdose (Cp12h) for multiple-dose TPV/r and multiple-dose CLR, indicating the effect of TPV/r on the CLR parameters, were 1.19 (1.04-1.37), 0.95 (0.83-1.09), and 1.68 (1.42-1.98), respectively. The formation of the metabolite 14-OH-CLR was decreased by 95% in the presence of TPV, and the TPV AUC increased 66% compared to that for human immunodeficiency virus (HIV)-negative historical controls. The FCZ study was conducted with 20 subjects. The GMR (and 90% CI) of the AUC, Cmax, and Cp24h, indicating the effect of multiple-dose TPV/r on the multiple-dose FCZ parameters, were 0.92 (0.88-0.95), 0.94 (0.91-0.98), and 0.89 (0.85-0.92), respectively. The TPV AUC increased by 50% compared to that for HIV-negative historical controls. The RFB study was conducted with 24 subjects. The GMR (and 90% CI) of the AUC, Cmax, and Cp12h for multiple-dose TPV/r and single-dose RFB, indicating the effect of TPV/r on the RFB parameters, were 2.90 (2.59-3.26), 1.70 (1.49-1.94), and 2.14 (1.90-2.41), respectively. The GMR (and 90% CI) of the AUC, Cmax, and Cp12h of TPV/r and RFB with 25-O-desacetyl-RFB were 4.33 (3.86-4.86), 1.86 (1.63-2.12), and 2.76 (2.44-3.12), respectively. Coadministration of TPV with a single dose of RFB resulted in a 16% increase in the TPV Cp12h compared to that for TPV alone. In the general population, no dose adjustments are necessary for the combination of TPV/r and CLR or FCZ. Combining TPV/r with RFB should be done with caution, while toxicity and RFB drug levels should be monitored. Study medications were generally well-tolerated in these studies.

* Corresponding author. Mailing address: The Ottawa Hospital, General Campus, Division of Infectious Diseases, CIU, Mailbox 223, 501 Smyth Rd., Ottawa, ON K1H 8L6, Canada. Phone: (613) 737-8899, ext. 71893. Fax: (613) 737-8696. E-mail: claporte{at}ohri.ca

{triangledown} Published ahead of print on 17 November 2008.

Antimicrobial Agents and Chemotherapy, January 2009, p. 162-173, Vol. 53, No. 1
0066-4804/09/$08.00+0     doi:10.1128/AAC.00534-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»